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 CURRENTOPINION Increasing healthcare costs: can we influence the
costs of glaucoma care?
Marc To¨teberg-Harmsa, Michael S. Berlinb,c, and Frances Meier-Gibbonsd
Purpose of review
Despite a decrease in real average growth rates per capita since 2009, healthcare costs continue to rise
worldwide. Numerous patient-related and doctor-related factors have contributed to this rise. Glaucoma is
the leading cause of irreversible blindness and requires chronic, usually lifelong treatment. As with other
chronic diseases, the adherence to prescribed treatment is often low and maybe influenced by the cost of
the therapy. The purpose of this review is to seek potential solutions to best control the escalating costs of
glaucoma care.
Recent findings
The studies we selected for this review can be divided into four different categories: costs of diagnostic
tests; costs of direct comparisons between drugs or laser and conventional surgery; patient-related factors
(such as adherence); and general aspects regarding costs: theoretical models and calculations.
Summary
It is challenging to find reliable studies concerning this subject matter. As patients are under the umbrellas
of variously organized healthcare systems which span different cultures, the costs between countries are
difficult to compare. However, one common aspect to lower costs in glaucoma care is to improve patient
adherence. Theoretical models with actual patient studies could enable cost reductions by comparing
multiple diagnostic and therapeutic scenarios.
Video abstract
http://links.lww.com/COOP/A22.
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INTRODUCTION
When reviewing overall healthcare costs worldwide,
two sources of statistics are most often cited: the
Organization for Economic Cooperation and Devel-
opment (OECD) and theWorldHealthOrganization
(WHO).
The OECD compares data of 34 industrialized
countries. The total costs of healthcare can be pres-
ented as a percentage of the gross domestic product
(GDP; measure of the total economy of a nation) or
as expenditures per capita. Eighteen percent of the
world population lives in countries belonging to the
OECD. The average health spending as a share of
GDP of the OECD countries was 8.9% (2013) and
the average per capita expenditure was US$3453
(2012) [1].
The WHO presented the figures of 2012 in a
global overview [2]. The total global expenditures
for health were US$6.5 trillion with a per capita
expenditure of US$948 per year with a significant
discrepancy between the country with the lowest
spending (Eritrea: US$12) and the highest (United
States of America: US$8362).
Since 2009, and in part because of economic
crises, average healthcare costs have steadily
increased worldwide despite a decrease of the real
average growth rates per capita. Numerous causes
exist on both, the patient’s and doctor’s sides, con-
tributing to these rising healthcare costs.
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Both average age and individuals’ expectations
are growing, and their overall health is better than in
previous years. In addition, there are better diag-
nostic means and treatment options available. The
combination of these factors leads to an increase in
total healthcare costs.
Glaucoma is the leading cause of irreversible
blindness worldwide and its prevalence is rising
[3,4]. It is estimated that in the year 2020, 80million
patients will be affected by the disease [4]. In
addition, other estimates contend that at least
50% of all patients do not know that the disease
affects them [5]. Glaucoma creates direct costs as
well as indirect costs. The direct costs include
expenses for diagnostic tests and therapy, whereas
indirect costs have several sources: costs for the
individuals taking care of glaucoma patients; and
alternatively costs for consecutive problems (e.g.,
depression triggered by the diagnosis, increased
incidence of falls, and inability to drive).
Considering increasingly limited healthcare
budgets, greater solutions will be mandatory to
reduce costs for the management of our glaucoma
patients. The goal of this review is to review current
publications related to these issues.
METHODS
A literature search was conducted using MEDLINE
and http://www.google.com on August 18th 2016.
Search strings were ‘glaucoma’ and ‘costs’. Forty-two
articles were found onMEDLINE published between
January 2015 and July 2016. Manuscripts, which
were not written in English (n¼2), were excluded.
From the remaining 40 publications screened, 16
manuscripts were selected which contained infor-
mation on glaucoma and related healthcare costs.
COSTS OF DIAGNOSTIC TESTS
Heidelberg retinal tomography II vs.
glaucoma diagnostics in diagnosing
glaucoma
Mokhtari-Payam [6] et al. performed an analysis on
cost–effectiveness of Heidelberg retinal tomography
(HRT) II vs. glaucoma diagnostics (GDx) for diag-
nosing glaucoma in Iran. The study compared costs
of one hospital using HRT and a second hospital
using GDx. The authors came to the conclusion that
‘HRT II provided diagnostic accuracy at a lower cost
than GDx’. [6].
Tele-glaucoma screening
Thomas et al. [7
&
] compared costs and physician
time for teleglaucoma screening in rural Canada
compared with in-person visits. They found tele-
glaucoma screening to reduce costs, increase access
to ophthalmic care, and improve healthcare service
efficiency, specifically in rural areas [7
&
]. Thus, tele-
glaucoma screening could reduce cost and effec-
tively improve the quality of life.
Automated imaging technologies for the
diagnosis: the Glaucoma Automated Tests
Evaluation (GATE) study
Azuara-Blanco et al. [8] focused on this topic for the
National Institute for Health Research in Great Brit-
ain. Their report compared diagnostic performance
and cost–effectiveness of imaging technologies as
triage composite test for identifying people with
glaucoma [8]. The triage tests included: first, imag-
ing with HRT, using glaucoma probability score
(HRT-GPS) and Moorfields regression analysis
(HRT-MRA), second, scanning laser polarimetry
GDx, and third, optical coherence tomography
(OCT). The comparator was a triage test with a
clinical examination performed by a glaucoma
specialist plus visual field testing and intraocular
pressure (IOP) measurement. They noted two find-
ings: first, automated imaging can be effective as an
aid to diagnose glaucoma among individuals
referred from the community to hospital eye clinics
and second, amodel of care using a triage composite
test appears to be cost effective [8].
COSTS OF DIRECT COMPARISONS
BETWEEN DRUGS OR LASER AND
CONVENTIONAL SURGERY
Laser trabeculoplasty vs. medical treatment
Schultz et al. [9
&
] compared short-term costs of laser
trabeculoplasty (4743 patients) and medication
KEY POINTS
 Comparing healthcare costs in different countries is
challenging because of wide ranges of reimbursement
models, amounts, and insurance systems.
 Typically, studies are focused solely on comparing two
different treatment modalities, for example lasers vs.
medications or conventional surgery vs. medications.
Direct, indirect, and quality of life costs are seldom
included. Furthermore, the studies compiled do not use
a standardized protocol.
 The combination of a growing elderly population with
an increasing number of glaucoma patients combined
with general financial limitations of healthcare systems
require well-designed studies to optimize glaucoma
treatment so that cost–effectiveness may ultimately
be determined.
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management (16484 patients) for open-angle
glaucoma in the USA (commercial insurance and
Medicare supplemental insurance beneficiaries).
The group identified poor adherence, younger
age, and more comorbidities as predictors of receiv-
ing laser trabeculoplasty. Medication use was
reduced after laser trabeculoplasty. However, they
did not identify cost savings by laser trabeculoplasty
compared with medical treatment. Furthermore,
laser trabeculoplasty may not be advantageous in
resolving poormedication adherence, given that the
majority of patients (80%) require supplementary
treatment with topical drops within 2 years of
treatment.
Generic and branded glaucoma drops
Queen et al. [10] evaluated discrepancies in doses per
bottle, bottle fill volume, and cost among branded
and generic formulations of latanoprost in Texas,
USA. Annual cost and number of doses per bottle
(factors important to patients) vary significantly
depending on the manufacturer of the latanoprost
[10].
Surgery vs. medical treatment
Kaplan et al. [11] compared cost–effectiveness of
Baerveldt glaucoma implants, trabeculectomy with
Mitomycin C, and medical treatment. Trabeculec-
tomy and the Baerveldt implant are cost effective
comparedwithmedical treatment alone, but require
the willingness to pay US$50000 per quality-
adjusted life-years (QALYs). However, trabeculec-
tomy is at a substantially lower cost per QALY
compared with the Baerveldt implant.
Cost–effectiveness of cataract surgery in
advanced glaucoma
A study from Shanghai, China prospectively
reviewed cost–effectiveness of cataract surgery in
advanced glaucoma [12]. The follow-up was limited
to 3months. They concluded that cataract surgery is
highly cost effective in these patients and helped to
obtain more QALYs [12]. Nevertheless, the study is
based on short-term data only. It is well known that
the IOP-lowering efficacy of cataract surgery alone is
time limited. Considering that, the study results
could be quite different were longer-term results
compared.
Cost–effectiveness of combined cataract
surgeryR iStent implantation
A 3-year study from Manchester, United Kingdom
compared costs of surgery vs. costs of continuation
of medical glaucoma treatment [13]. The cost–
effectiveness varied depending on whether brand
or generic eye drops were used. Combined Phacoþ
iStent was only cost effective when generic medi-
cation was used as a comparator.
Fixed-combination drugs
An Indian study looked at combination of drugs in
primary open-angle glaucoma [14]. Combinations
of Dorzolamide plus Timolol, Brimonidine plus
Timolol, and Latanoprost plus Timolol were com-
pared. Brimonidine plus Timolol was found to be
most cost effective among three groups [14].
PATIENT RELATED FACTORS (SUCH AS
ADHERENCE)
Influence of Medicare Part D prescription
drug benefit on nonadherence in the United
States
A study by Blumberg et al. [15] aimed ‘to determine
whether the implementation of the Medicare Part D
prescription drug benefit affected rates of cost-
related nonadherence and cost-reduction strategies
in Medicare beneficiaries with and without glau-
coma and to evaluate associated risk factors for such
nonadherence’. Switching to another Medicare plan
led to reduction of cost-reduction strategies. The
study identified the following factors for nonadher-
ence: female gender, younger age, lower income,
self-reported visual disability, and a smaller Lawton-
Index (i.e., geriatric assessment of daily life acti-
vities). However, patients reporting failure to fill
prescriptions because of cost remained stable [15].
Influence of monetary enticement on
adherence
A group from Singapore has published a study pro-
tocol. The SIGMA study will search for evidence
on whether adherence-contingent rebates can
improve medication adherence among nonadher-
ent glaucoma patients [16]. Recruitment is currently
ongoing.
GENERAL ASPECTS REGARDING COSTS:
THEORETICAL MODELS AND
CALCULATIONS
Comparison of brand and generic drugs in
the United States and Canada
Schlenker et al. [17] compared costs of brand and
generic drugs in the United States and Canada. The
Increasing healthcare costs To¨teberg-Harms et al.
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major finding of this study is that brand drugs are
four-times more expensive in the United States
compared with Canada, whereas prices for generic
drugs are similar between both countries. Further-
more from 2006 to 2013, prices of brand drugs in the
United States increased by a greater extent com-
pared with Canada.
Healthcare utilization by glaucoma patients
A group in Taiwan compared healthcare utilization
by glaucoma patients and nonglaucoma patients in
Taiwan during a 1 year follow-up and compared
total healthcare costs of both groups [18]. The study
found that two-fold higher total costs were gener-
ated by greater healthcare utilization by glaucoma
patients.
Cost–effectiveness of treatment of ocular
hypertension
This review focused on the cost–effectiveness of
treatment for ocular hypertension [19]. The review
found contradictory results with no clear answer to
the objective of the review. A similar study con-
ducted in the United Kingdom found it adequate
to monitor ocular hypertension (OHT) not more
often than every 2 years [20]. Alternatively, primary
treatment and minimal monitoring were found to
be sufficient [20].
Economic burden of childhood glaucoma
This study analyzed costs in the United States of
America related to childhood glaucoma during the
first 4 years after diagnosis [21
&
]. The annual cost of
care of childhood glaucoma averagedUS$ 21441 per
patient [21
&
]. The highest contributors to such costs
were surgical interventions and examinations under
anesthesia (EUA). Costs were highest in the first year
after diagnosis.
Increase of costs because of changes in
demographics
Stein published a commentary on the hidden costs
and burdens of glaucoma based on Medicare data
[22]. He estimated a dramatic increase in costs
because of an aging population.
CONCLUSION
There are few studies, which focus on the question
of how the costs of glaucoma care could be effec-
tively contained. We divided the studies into four
different categories:
(1) Costs of diagnostic tests.
(2) Costs of direct comparisons between drugs or
laser and conventional surgery.
(3) Patient related factors (such as adherence).
(4) General aspects regarding costs: theoretical
models and calculations.
First, Mokhtari-Payam [6] studied the cost–
effectiveness of HRT II vs. GDx in two different
hospitals and found that HRT II was more cost
effective [6]. Comparing telemedicine with direct
patient contact, telemedicine appeared more cost
effective and could prevent 24% of blindness after
30 years
Azuara-Blanco [8] compared the diagnostic
accuracy, performance as a triage test, and cost–
effectiveness of automated imaging technologies.
They found that a composite triage test, including
imaging, visual acuity, and IOP measurements
would be more cost–effective than the current
system used.
Second, a US group looked at four different
latanoprost formulations (the original Xalatan
and three generics) in a comparative economic
evaluation [10]. They found that the number of
doses per bottle and the annual costs varied. This
is in accordance with older studies, in which they
found variations in the size of the drop and the size
of the bottle opening and the number of drops per
bottle. All of these factors influence the monthly
cost of a drug.
An Indian study compared three drug combi-
nations, and found that the combination of Brimo-
nidine/Timolol was most cost effective. They
calculated cost–effectiveness by cost per mm IOP
reduction [14].
Schultz presented a retrospective analysis of
laser trabeculoplasty vs. medical treatment. Laser
treatment was performed in younger patients with
low adherence. The patients receiving a laser treat-
ment used fewer antiglaucoma drugs; however, 80%
required additional antiglaucoma drugs 2 years after
the laser treatment. The question arose, however,
whether the results are significant, given that 48%of
the patients they examined were less than 65 years
of age (which is not representative of a typical
glaucoma population) [9
&
].
A Markov model (5-year horizon and 100000
glaucoma patients) was used to compare trabeculec-
tomy vs. tube shunt surgeries. At the level of US$
50000 per QUALY gained, both were cost effective,
whereas trabeculectomywas already cost effective at
a lower amount of money per QUALY gained [11].
A Chinese study found cataract surgery cost-
effective in lowering IOP in advanced glaucoma
patients. However, these findings contradict other
Glaucoma
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studies regarding the IOP-lowering efficacy of cata-
ract surgery [12].
A similar Manchester study came from calcu-
lated the cost effectiveness of phaco with a single
iStent after 3 years and compared the cost to the cost
of antiglaucoma drugs. Their conclusion was that
any cost advantage depended soley on the type of
drug used (brand vs. generic) [13].
Third, it is well recognized that adherence influ-
ences costs of treating glaucoma. Blumberg studied
the behavior of patients before and after changes in
insurance coverage for medication related to Med-
icare Plan D and found specific adherence patterns
in different patients [15].
Fourth, generic drugs are known to have, in
general, a lower price than brand drugs. A Canadian
study showed a four-fold higher price for brand
drugs than generic drugs. However, they found an
interesting result that the US brand drug prices
increased at a much greater rate than the Canadian
brand drugs during recent years [17].
Glaucoma patients created two-fold higher costs
utilizing healthcare facilities than nonglaucoma
patients in Taiwan. Outpatient visits and inpatient
days were included in these costs [18].
Tuulonen [19] reviewed the cost–effectiveness
of monitoring and treating ocular hypertension.
They created a simulation model with five different
pathways and recommended that confirmed OHT
patients need not be monitored more often than
every 2 years. As an alternative, they discussed
primary treatment with minimal monitoring to
assess treatment responsiveness (as measured by
IOP). Their conclusions regarding the cost–effec-
tiveness of treating OHT were inconclusive [19].
Liu analyzed the costs of treating childhood
glaucoma during the first 4 years after diagnosis.
He found that the overall costs were highest during
the first year after diagnosis [21
&
].
Through analyzing these various published
studies, we conclude that there is no single appro-
priate study design to answer the question of how
we can best constrain the costs of glaucoma care
while providing effective and adequate care.
Furthermore, it is very difficult to compare these
studies because of the diversity of the systems as
many are based on a particular healthcare reim-
bursement programme (such as Medicare in the
United States), which differ from other programmes
to vastly to allow comparison. Additionally, many
countries do not have a centralized healthcare sys-
tem, to enable cost data comparisons.
Following our analysis of these recent publi-
cations we conclude that additional studies are
necessary to improve our knowledge about costs
related to glaucoma care. The rapid growth in
number of MIGS procedures performed will add
another cost/benefit value in future such analyses.
Although, we assume that surgeries when compared
with medications or laser trabeculoplasty will likely
increase treatment costs in the short-term, these
procedures may lower total treatment costs in the
long-term, especially when considering adherence
issues [23]. However, at the moment, there are no
RCTs proving long-term efficacy (i.e., 3 years) for
the majority of the MIGS procedures. To answer
this question in the future, long-term data on the
efficacy of MIGS procedure with a standardized
protocol is needed. In addition, the variety of
reimbursement models among different countries
creates a challenging barrier to comparing total
healthcare costs and this variable is unlikely to be
resolvable.
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